表紙
市場調查報告書

醫藥品產業的夥伴關係,授權,投資,M&A交易趨勢

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2019

出版商 GlobalData 商品編碼 917887
出版日期 內容資訊 英文 110 Pages
訂單完成後即時交付
價格
Back to Top
醫藥品產業的夥伴關係,授權,投資,M&A交易趨勢 Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2019
出版日期: 2019年11月01日內容資訊: 英文 110 Pages
簡介

本報告提供醫藥品產業的夥伴關係,授權,投資,M&A交易趨勢的相關調查,交易的概要與各治療領域,各地區的趨勢等相關彙整。

第1章 目錄

第2章 2019年第3季減少的醫藥品、醫療保健產業的交易

第3章 全球醫藥品、醫療保健產業的交易摘要

第4章 各類型全球醫藥品、醫療保健產業的交易摘要

  • M&A
  • 各治療
  • 發行股票
  • 創業投資
  • 私人、股權

第5章 全球醫藥品、醫療保健產業的合作交易

第6章 全球醫藥品、醫療保健產業的授權契約

第7章 各治療交易摘要

  • 腫瘤
  • 中樞神經系統
  • 感染疾病
  • 免疫學
  • 代謝性疾病
  • 心血管
  • 腸胃
  • 皮膚科
  • 呼吸系統
  • 眼科

第8章 各地區交易摘要

  • 北美
  • 歐洲
  • 亞太地區
  • 其他

第9章 高級顧問

第10章 進一步資訊

目錄
Product Code: GDHC0554QD

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2019" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q3 2019.

The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the five quarters.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1.Table of Contents

  • 1.1. List of Tables 5
  • 1.2. List of Figures 7

2. Deals in Pharmaceutical & Healthcare Industry Decreased in Q3 2019 9

  • 2.1. Pharmaceuticals & Healthcare, Deal Summary, Q3 2019 9

3. Pharmaceuticals & Healthcare, Global, Deal Summary, Q3 2019 13

  • 3.1. Pharmaceuticals & Healthcare, Global, Deals Analysis, Q3 2019 13
  • 3.2. Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q3 2019 15
  • 3.3. Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q3 2019 16
  • 3.4. Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2019 17
    • 3.4.1. Amgen to Acquire Rights to Otezla from Celgene for USD13.4 Billion 17
    • 3.4.2. Gilead Sciences and Galapagos Enter into R&D Agreement 17
    • 3.4.3. Thermo Fisher Scientific Raises USD5.7 Billion in Public Offering of Notes 18
    • 3.4.4. China Biologic Products Receives Non-Binding Acquisition Proposal from Buyer Group 19
    • 3.4.5. Sumitomo Dainippon Pharma to Acquire 10% Stake in Roivant Sciences for USD3 Billion 19

4. Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 21

  • 4.1. Pharmaceuticals & Healthcare, Global, M&A, Q3 2019 21
    • 4.1.1. Top M&A Deals in Q3 2019 22
    • 4.1.3. Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q3 2018 - Q3 2019 23
  • 4.2. Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q3 2019 24
    • 4.2.1. Top Initial Public Offerings in Q3 2019 25
    • 4.2.2. Top Secondary Offerings in Q3 2019 25
    • 4.2.3. Top PIPE Deals in Q3 2019 26
    • 4.2.4. Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q3 2018 - Q3 2019 27
  • 4.3. Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q3 2019 29
    • 4.3.1. Top Venture Financing Deals in Q3 2019 30
    • 4.3.3. Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2019 31
    • 4.3.4. Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2019 33
    • 4.3.6. Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q3 2018 - Q3 2019 34
    • 4.3.7. Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q3 2018 - Q3 2019 35
    • 4.3.8. Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q3 2018 - Q3 2019 36
  • 4.5. Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q3 2019 37
    • 4.5.1. Top Private Equity Deals in Q3 2019 38
    • 4.5.2. Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q3 2018 - Q3 2019 39

5. Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2019 40

  • 5.1. Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2019 40
  • 5.2. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q3 2018 - Q3 2019 41
  • 5.3. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2019 43
    • 5.3.1. Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q3 2019 44
    • 5.3.2. Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2019 44
    • 5.3.3. Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q3 2019 45
  • 5.5. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2018 - Q3 2019 46
  • 5.6. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q3 2018 - Q3 2019 48
  • 5.7. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q3 2018 - Q3 2019 49
  • 5.8. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2018 - Q3 2019 50

6. Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q3 2019 52

  • 6.1. Pharmaceutical & Healthcare, Global, Licensing Agreements, Q3 2019 52
  • 6.2. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2018 - Q3 2019 53
    • 6.2.1. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q3 2019 54
    • 6.2.2. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q3 2019 54
    • 6.2.3. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q3 2019 55
  • 6.3. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q3 2018 - Q3 2019 56
  • 6.4. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q3 2018 - Q3 2019 57
  • 6.5. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2018 - Q3 2019 59
  • 6.6. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2018 - Q3 2019 60
  • 6.7. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q3 2018 - Q3 2019 62

7. Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 64

  • 7.1. Pharmaceuticals & Healthcare, Global, Oncology Deals, Q3 2019 64
    • 7.1.1. Oncology - Deals of the Quarter 65
  • 7.2. Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q3 2019 67
    • 7.2.1. Central Nervous System - Deals of the Quarter 68
  • 7.3. Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q3 2019 70
    • 7.3.1. Infectious Disease - Deals of the Quarter 71
  • 7.4. Pharmaceuticals & Healthcare, Global, Immunology Deals, Q3 2019 74
    • 7.4.1. Immunology - Deals of the Quarter 75
  • 7.5. Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q3 2019 77
    • 7.5.1. Metabolic Disorders - Deals of the Quarter 78
  • 7.6. Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q3 2019 80
    • 7.6.1. Cardiovascular - Deals of the Quarter 81
  • 7.7. Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q3 2019 82
    • 7.7.1. Gastrointestinal - Deals of the Quarter 83
  • 7.8. Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q3 2019 84
    • 7.8.1. Dermatology - Deals of the Quarter 85
  • 7.9. Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q3 2019 87
    • 7.9.1. Respiratory - Deals of the Quarter 88
  • 7.10. Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q3 2019 90
    • 7.10.1. Ophthalmology - Deals of the Quarter 91

8. Deal Summary by Geography 92

  • 8.1. Pharmaceuticals & Healthcare, North America Region, Deals, Q3 2019 92
    • 8.1.1. North America - Deals of the Quarter 93
  • 8.2. Pharmaceuticals & Healthcare, Europe Region, Deals, Q3 2019 95
    • 8.2.1. Europe - Deals of the Quarter 96
  • 8.3. Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q3 2019 97
    • 8.3.1. Asia-Pacific - Deals of the Quarter 98
  • 8.4. Pharmaceuticals & Healthcare, Rest of the World, Deals, Q3 2019 100
    • 8.4.1. Rest of the World - Deals of the Quarter 101

9. Pharmaceuticals & Healthcare, Global, Top Advisors 102

  • 9.1. Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Q3 2018 - Q3 2019 102
  • 9.2. Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Q3 2018 - Q3 2019 104

10. Further Information 106

  • 10.1. Methodology 106
  • 10.2. About GlobalData 106
  • 10.3. Contact Us 107
  • 10.4. Disclosure information 107
  • 10.5. Disclaimer 107

List of Tables

  • Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q3 2018 - Q3 2019 14
  • Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q3 2019 16
  • Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2019 17
  • Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 22
  • Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q3 2019 22
  • Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q3 2018 - Q3 2019 23
  • Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2018 - Q3 2019 25
  • Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q3 2019 25
  • Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q3 2019 25
  • Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q3 2019 26
  • Table 11: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2018 - Q3 2019 28
  • Table 12: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 30
  • Table 13: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q3 2019 30
  • Table 14: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q3 2019 33
  • Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2018 - Q3 2019 34
  • Table 16: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 35
  • Table 17: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q3 2018 - Q3 2019 36
  • Table 18: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 37
  • Table 19: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q3 2019 38
  • Table 20: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2018 - Q3 2019 39
  • Table 21: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 41
  • Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 42
  • Table 23: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2018 - Q3 2019 43
  • Table 24: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2019 44
  • Table 25: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2019 44
  • Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q3 2019 45
  • Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2018 - Q3 2019 47
  • Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2018 - Q3 2019 49
  • Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2018 - Q3 2019 51
  • Table 30: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 52
  • Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2018 - Q3 2019 53
  • Table 32: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q3 2019 54
  • Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q3 2019 54
  • Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q3 2019 55
  • Table 35: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 56
  • Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q3 2018 - Q3 2019 58
  • Table 37: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2018 - Q3 2019 61
  • Table 38: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2018 - Q3 2019 63
  • Table 39: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 65
  • Table 40: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 68
  • Table 41: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 71
  • Table 42: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 75
  • Table 43: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 78
  • Table 44: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 81
  • Table 45: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 83
  • Table 46: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 85
  • Table 47: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 88
  • Table 48: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 91
  • Table 49: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 93
  • Table 50: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 96
  • Table 51: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 98
  • Table 52: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 101
  • Table 53: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 103
  • Table 54: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 105

List of Figures

  • Figure 1: Pharmaceuticals & Healthcare, Number Of Deals, Q3 2018 - Q3 2019 10
  • Figure 2: Pharmaceuticals & Healthcare, Licensing Deals By Payment Mode, Q3 2018 - Q3 2019 11
  • Figure 3: Pharmaceuticals & Healthcare, Number Of Deals by Markets, Q3 2019 11
  • Figure 4: Pharmaceuticals & Healthcare, Number Of Deals by Region, Q3 2019 12
  • Figure 5: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q3 2018 - Q3 2019 13
  • Figure 6: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q3 2019 15
  • Figure 7: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q3 2019 16
  • Figure 8: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q3 2018 - Q3 2019 21
  • Figure 9: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q3 2018 - Q3 2019 23
  • Figure 10: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 24
  • Figure 11: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), Q3 2018 - Q3 2019 27
  • Figure 12: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 29
  • Figure 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q3 2019 31
  • Figure 14: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q3 2019 33
  • Figure 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q3 2018 - Q3 2019 34
  • Figure 16: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 35
  • Figure 17: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 37
  • Figure 18: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q3 2018 - Q3 2019 39
  • Figure 19: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 40
  • Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 41
  • Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2018 - Q3 2019 43
  • Figure 22: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2018 - Q3 2019 46
  • Figure 23: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2018 - Q3 2019 48
  • Figure 24: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2018 - Q3 2019 49
  • Figure 25: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2018 - Q3 2019 50
  • Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 52
  • Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2018 - Q3 2019 53
  • Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 56
  • Figure 29: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2018 - Q3 2019 57
  • Figure 30: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q3 2018 - Q3 2019 59
  • Figure 31: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q3 2018 - Q3 2019 60
  • Figure 32: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2018 - Q3 2019 62
  • Figure 33: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 64
  • Figure 34: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 67
  • Figure 35: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 70
  • Figure 36: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 74
  • Figure 37: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 77
  • Figure 38: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 80
  • Figure 39: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 82
  • Figure 40: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 84
  • Figure 41: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 87
  • Figure 42: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 90
  • Figure 43: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 92
  • Figure 44: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 95
  • Figure 45: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 97
  • Figure 46: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 100
  • Figure 47: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 102
  • Figure 48: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q3 2018 - Q3 2019 104
Back to Top